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Many bacteria use quorum sensing (QS), a bacterial communication system based on
the diffusion and perception of small signaling molecules, to synchronize their behavior
in a cell-density dependent manner. QS regulates the expression of many genes
associated with virulence factor production and biofilm formation. This latter is known
to be involved in antibiotic and phage resistance mechanisms. Therefore, disrupting
QS, a strategy known as quorum quenching (QQ), appears to be an interesting way
to reduce bacterial virulence and increase antibiotic and phage treatment efficiency. In
this study, the ability of the QQ enzyme SsoPox-W263I, a lactonase able to degrade
acyl-homoserine lactones, was investigated for quenching both virulence and biofilm
formation in clinical isolates of Pseudomonas aeruginosa from diabetic foot ulcers,
as well as in the PA14 model strain. These strains were further evolved to resist
to bacteriophage cocktails. Overall, 10 antibiotics or bacteriophage resistant strains
were evaluated and SsoPox-W263I was shown to decrease pyocyanin, protease and
elastase production in all strains. Furthermore, a reduction of more than 70% of biofilm
formation was achieved in six out of ten strains. This anti-virulence potential was
confirmed in vivo using an amoeba infection model, showing enhanced susceptibility
toward amoeba of nine out of ten P. aeruginosa isolates upon QQ. This amoeba
model was further used to demonstrate the ability of SsoPox-W263I to enhance the
susceptibility of sensitive and phage resistant bacteria to bacteriophage and antibiotic.
Keywords: quorum quenching, quorum sensing, lactonase, AHL, Pseudomonas aeruginosa, multidrug resistant
bacteria, antibiotics, bacteriophages
INTRODUCTION
Pseudomonas aeruginosa is an opportunistic human pathogen involved in numerous diseases from
otitis to keratitis, wound and burn infections, pneumonia and urinary tract infections (Driscoll
et al., 2007). P. aeruginosa isolates are among the most frequently found antibiotic-resistant
pathogens involved in diabetic foot infections, their presence is usually associated with morbidity
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(Ertugrul et al., 2012). Surveillance of P. aeruginosa infections has
revealed trends of increasing resistance to antibiotic treatments
(Breidenstein et al., 2011) and the priority to support research
and development of effective drugs against antibiotic-resistant
P. aeruginosa was recently defined as critical by the World Health
Organization (WHO) (Tacconelli et al., 2018).
This last decade, bacteriophage (phage) therapy has regained
interest as a new weapon to treat antibiotic-resistant infections
(Rolain et al., 2015; Domingo-Calap et al., 2016) and is under
consideration to treat P. aeruginosa infections. Phages are the
most abundant predator of bacteria in nature (Suttle, 2005)
and have been domesticated, especially in Eastern Europe, to
treat enteric infections, such as cystic fibrosis (Rolain et al.,
2015), dysentery (Salmond and Fineran, 2015), diabetic foot
infection, chronic osteomyelitis and other surgical and wound
infections (Kutter et al., 2010). Phages offer the advantage of
specifically targeting their host bacteria by being harmless to the
commensal flora (Loc-Carrillo and Abedon, 2011) and human
cells (Domingo-Calap et al., 2016). In western countries, clinical
trials have been conducted to assay the therapeutic potential
of phages (Rhoads et al., 2009; Wright et al., 2009; Kakasis
and Panitsa, 2018), for example to treat P. aeruginosa infected
burns (Jault et al., 2018). However, as for antibiotics, phages
suffer resistance phenomena that may hinder the development
of bacteriophage-based therapy (Jault et al., 2018). Finding
new therapeutic strategies to limit bacterial resistance is thus
of great interest.
In this way, another alternative to treat P. aeruginosa
infections aims to highjack its communication system referred
to as quorum sensing (QS). In P. aeruginosa, QS mainly relies
on the secretion and perception of N-acyl homoserine lactones
(AHL) to orchestrate its behavior, including virulence and biofilm
formation as well as the CRISPR-Cas defense system, in a cell-
density dependent manner (Bassler and Losick, 2006; Høyland-
Kroghsbo et al., 2017). Interconnections between bacterial QS
and susceptibility to bacteriophage infections were also identified
(Qin et al., 2017; Saucedo-Mora et al., 2017). Disrupting QS,
a strategy referred to as quorum quenching (QQ), is highly
attractive to counteract bacterial virulence by using QS inhibitors
(QSI) or QQ enzymes (QQE). Among QQE, special attention
has been paid to the robust lactonase SsoPox-W263I (Hiblot
et al., 2013) that was proved to efficiently inhibit virulence
in vitro in model and clinical strains of P. aeruginosa (Guendouze
et al., 2017) and to drastically decrease mortality in a rat
pulmonary infection model (Hraiech et al., 2014). Furthermore,
the impact of SsoPox-W263I on CRISPR-Cas gene expression
of P. aeruginosa was recently demonstrated in both model and
clinical strains suggesting that enzymatic QQ may modulate
bacterial susceptibility to bacteriophages (Mion et al., 2019).
Here, we consider the use of SsoPox-W263I in clinical isolates
of P. aeruginosa from diabetic foot ulcers together with the
model strain PA14 and further evolved these strains to resist
bacteriophages. Knowing that the evolutionary selection of phage
resistance in bacteria can induce phenotypic shifts (Labrie et al.,
2010), we focused our interest on determining the potential of
QQ to control antibiotic and phage-resistant bacteria. Our results
show that SsoPox-W263I is efficient to decrease virulence or
biofilm in these multi-resistant strains, both in vitro and in vivo
using an amoeba model. In the last part, we investigate the
QQE treatment to enhance the therapeutic effect of antibiotic
and phage when used as a co-treatment in the amoeba infection
model. This study shows that QQ is an interesting strategy to treat
bacterial infections that can be used to strengthen the effect of
antimicrobial treatments.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Experiments were conducted using model strain PA14 and
three clinical isolates of P. aeruginosa, isolated from diabetic
patients of the Nimes University Hospital presenting diabetic
foot infections. All the patients received an oral information,
were anonymized and gave a non-opposition statement to
bacterial storage. This study was approved by the local ethics
committee (South Mediterranean III) and was carried out
in accordance with the Declaration of Helsinki as revised
in 2008. Clinical isolates of P. aeruginosa and model strain
PA14 (UCBPP-PA14) were inoculated from a single colony
and pre-cultivated during 6 h at 37◦C in Luria Bertani
(LB) medium (10 g l−1 NaCl, 10 g l−1 Tryptone, 5 g l−1
yeast extract) with agitation at 650 rpm. Then, precultures
were diluted by a 1,000 factor in MOPS minimal medium
complemented with nitrogen (15 mM NH4Cl), iron (5 µM
Fe2SO4), phosphate (4 mM K2HPO4) and glutamate (25 mM)
as carbon source (MOPS glutamate) (Welsh and Blackwell, 2016)
and cultures were incubated at 37◦C under agitation at 650 rpm.
Enzymes were added, when indicated, at 0.5 mg ml−1. For
virulence factor and biofilm formation analysis cultures were
incubated during 20 h.
Phage Production and Isolation
A bacteriophage cocktail (Intesti-bacteriophage, Microgen,
Russia) was used for this study. Isolated phage 8Intesti-PA14
corresponds to the isolation and concentration of plaque-forming
unit (PFU) formed by the phage cocktail on P. aeruginosa PA14
according to the following protocol.
The double agar overlay plaque assay was used to determine
the phage titer and isolate phages from phage cocktail (Kropinski
et al., 2009). 500 µl of an overnight culture of bacteria was added
to 4.5 ml of molten soft LB-agar (0.75%) and overlaid onto a
hard LB-agar plate. Once dry, 10 µl drops of phage cocktail
were spotted on the soft LB-agar layer. Plates were incubated
overnight at 37◦C. Lytic plaques were collected and suspended
in 500 µl of MgSO4 (10 mM). After chloroform treatment and
10 min of centrifugation at 4,500 g, the supernatant was filtered
at 0.22 µm. The resulting phage suspension was again spotted
on a double-layer plate, and the experiment was repeated until a
108 PFU ml−1 suspension was obtained. To estimate the phage
titer, serial dilutions (from 100 to 10−10) of phage suspension
were performed in MgSO4 (10 mM), then 10 µl of each dilution
was spotted on the double-layer plate. The plate was incubated
overnight at 37◦C. The titer (PFU ml−1) was determined by the
calculation of lytic PFU for 1 ml of phage suspension.
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Isolation of Phage Resistant
P. aeruginosa Bacteria
Precultures were performed by inoculating one colony of
the initial strains in LB medium during 6–8 h, then the
precultures were diluted by a 10,000 factor in MOPS glutamate,
3 ml were transferred in each well of a 12-well plate. 10,
50, or 100 µl of bacteriophage containing cocktail (Intesti-
bacteriophage, Ìicrogen, Russia) were added to each well. The
plate was incubated at 37◦C overnight under agitation at 650 rpm.
The OD 600 nm was then measured using a plate reader (Synergy
HT, BioTek). Cultures showing complete lysis were diluted in a
solution of phosphate saline buffer (PBS) and 20% glycerol. The
dilutions were then plated on LB agar. Plates were incubated at
37◦C overnight.
After 16 h of incubation, the isolated colonies were picked,
cultivated in LB medium and stocked in 20% glycerol at−150◦C.
The tolerance of the isolated bacteria to the phage cocktail
was verified by exposing the strains to the same conditions as
those used for their isolation and by verifying that the final OD
600 nm was indeed higher for the resistant strain than for the
parental strain.
Protein Production and Purification
Two SsoPox variants namely W263I and 5A8 were used as QQ
and inactive enzymes, respectively. Productions were realized
as previously described (Hiblot et al., 2012, 2013; Hraiech
et al., 2014). Briefly, Escherichia coli BL21 (DE3)-pGro7/GroEL
cells (TaKaRa), carrying plasmid pET22b-SsoPox-W263I or
pET22b-SsoPox-5A8, were cultivated in ZYP-5052 medium
complemented with 100 µg ml−1 ampicillin and 34 µg ml−1
chloramphenicol at 37◦C until OD 600 nm reached 0.8–1. The
expression of chaperone proteins was induced by adding L-
arabinose at a final concentration of 0.2% (w/v). At the same
time, the temperature was reduced to 23◦C and 0.2 mM of
CoCl2 was added. After 20 h of incubation, the cells were
harvested by centrifugation (4,400 g, 4◦C, 20 min), the pellet
was resuspended in lysis buffer [50 mM HEPES pH 8, 150 mM
NaCl, 0.25 mg ml−1 lysozyme, 0.1 mM Phenylmethylsufonyl
fluoride (PMSF) and 10 mg ml−1 DNaseI] and stored at
−80◦C during 16 h. Frozen cells were thawed at 37◦C during
15 min and lysed by three steps of 30 s sonication (QSonica
sonicator Q700, amplitude at 45). Cell debris were removed
by centrifugation (21,000 g, 4◦C, 15 min). Crude extract was
incubated during 30 min at 80◦C and then centrifuged to
precipitate E. coli proteins (21,000 g, 4◦C, 30 min). The enzyme
was then concentrated by overnight incubation at 4◦C in 75%
ammonium sulfate. After resuspension in activity buffer (50 mM
HEPES pH 8, 150 mM NaCl, 20.2 mM CoCl2) ammonium
sulfate was eliminated by desalting (HiPrep 26/10 desalting,
GE Healthcare, ÄKTA Avant). The protein sample obtained
was concentrated to 2 ml and then loaded on a size-exclusion
chromatography column and purified to homogeneity (HiLoad
16/600 SuperdexTM 75pg, GE Healthcare, ÄKTA Avant). Protein
purity was checked by migration on 10% SDS-PAGE and
protein concentration was measured using a spectrophotometer
NanoDrop 2000 (Thermo Scientific).
Antibiograms
Antibiotic sensitivity of the strains was determined on
a Mueller Hinton agar (BioMerieux). The disk diffusion
method was realized using the following antibiotics: amikacin
(30 µg), cefepime (30 µg), ceftazidime (30 µg), ciprofloxacin
(5 µg), doxycycline (30 µg), fosfomycin (50 µg), imipenem
(10 µg), nitrofurantoin (300 µg), piperacillin/tazobactam
(85 µg), ticarcillin (75 µg), ticarcillin/clavulanate (85 µg),
trimethoprim/sulfamethoxazole (25 µg), tobramycin (10 µg),
rifampicin (30 µg). The results were interpreted according
to the EUCAST guidelines (European Society of Clinical
Microbiology and Infectious Diseases, 20181) using the Scan R©
1200 (Interscience) (Diop et al., 2016).
Analysis of Virulence Factor Production
Virulence factor productions for the different strains were
determined in vitro after a 20-h culture in presence of
0.5 mg ml−1 SsoPox-W263I or inactive mutant SsoPox-
5A8 as control.
Pyocyanin Production
Cell-free culture supernatants were prepared by centrifugation
for 5 min at 12,000 g. Pyocyanin was extracted by mixing 500 µl
of cell-free supernatant with 250 µl of chloroform (Price-Whelan
et al., 2007). After vortexing and 5 min of centrifugation at
12,000 g, 200 µl of the bottom chloroform phase were transferred
into a quartz 96-well plate. The absorbance was measured at
690 nm using a plate reader (Synergy HT, BioTek).
Proteolytic Activity
The protease activity was measured using azocasein (Sigma)
(Chessa et al., 2000). 675 µl of PBS solution pH 7 were mixed
with 50 µl of azocasein (30 mg ml−1 in water) and 25 µl of cell-
free supernatant. After 2 h of incubation at 37◦C, 125 µl of 20%
(w/v) trichloroacetic acid were added to stop the reaction. The
solution was then centrifugated for 10 min at 10,000 g and the
absorbance of 200 µl of the supernatant was measured at 366 nm
using a plate reader (Synergy HT, BioTek).
Elastolytic Activity
Elastase B activity was measured using elastin-Congo red
conjugate (Sigma) degradation assay (Smith et al., 2003). 50 µl of
cell-free supernatant were added to 150 µl of elastin-Congo red
solution (5 mg ml−1 in 10 mM Tris–HCl and 1 mM CaCl2 buffer
at pH 7.2) into a 96-well plate. The plate was then sealed with an
aluminum membrane and incubated during 24 h at 37◦C under
agitation (300 rpm). After sedimentation of undigested elastin-
Congo red conjugate 100 µl of the upper phase was transferred
to an empty well and the absorbance was measured at 490 nm
using a plate reader (Synergy HT, BioTek).
Biofilm Formation
The biofilm formed in each well was quantified using crystal
violet (Sigma) staining as previously described (Stepanovic´ et al.,
2000). Briefly, planktonic cells (non-attached) were first removed
1http://www.eucast.org/clinical_breakpoints/
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by washing the wells with 4 ml of PBS. The plates were then
dried at 37◦C and the biofilm was stained by adding 4 ml of
crystal violet 0.05%, incubated for 3 min under agitation at
150 rpm. Then, the crystal violet was removed and each well was
rinsed with 4 ml of PBS. Crystal violet was then resolubilized
by adding 3 ml of ethanol 96%. 200 µl of the solution was
transferred to a 96-well plate and the final concentration of
crystal violet was measured at OD 595 nm using a plate reader
(Synergy HT, BioTek).
Virulence Assay Toward Amoeba
In vivo virulence assay was adapted from a previously described
procedure using P. aeruginosa and Acanthamoeba polyphaga Linc
AP1 (Fenner et al., 2006). Briefly, 3 ml of bacterial culture were
pelleted down and resuspended in Page’s amoeba saline (PAS)
buffer (2 mM NaCl, 16 µM MgSO4, 27 µM CaCl2, 0.53 mM
Na2HPO4, 1 mM KH2PO4, pH 6.9) after a culture in 6-well
plates (NuncTM, Thermo Scientific). A. polyphaga Linc AP1 was
cultivated during 2–3 days into peptone yeast extract glucose
(20 g l−1 proteose peptone, 2 g l−1 yeast extract, 0.1 M glucose,
4 mM MgSO4, 0.53 mM CaCl2, 3.4 mM sodium citrate, 50 µM
(NH4)2Fe(SO4)2, 2.5 mM KH2PO4, 1.3 mM Na2HPO4, pH
6.8) medium at 28◦C (Fenner et al., 2006). Amoeba cells were
recovered after centrifugation at 750 g and resuspended into
PAS buffer to 105 cells µl−1. Then, 1 ml of bacterial suspension
was spread on a PAS agar plate and was left to dry at room
temperature. At the center of each plate, 5 µl of A. polyphaga
were spotted and dried at room temperature. Then, plates were
incubated at 30◦C over 7 days and amoeba propagation was
followed by directly measuring the central spot with a ruler.
To test the combinatory effect of enzymatic and antibiotic
treatments, the MOPS bacterial culture was treated with
10 µg ml−1 of enzyme (either SsoPox-W263I or inactive variant
SsoPox-5A8 as control) and 25 µg ml−1 ciprofloxacin was added
to PAS buffer during the resuspension step.
To test the combinatory effect of enzymatic and phage
treatments, the MOPS bacterial culture was treated with
10 µg ml−1 of enzyme (either SsoPox-W263I or inactive variant
SsoPox-5A8 as control) and 107 PFU ml−1 of 8Intesti-PA14
phage was added to PAS buffer during the resuspension step.
RESULTS
Evaluating Sensitivity of Clinical Isolates
to Antibiotics and Bacteriophage
Cocktail
PA14 is a model strain originally isolated from a burn wound
(Soyza et al., 2013) and B10, C5, and C11 were isolated from
diabetic foot ulcerations (Guendouze et al., 2017). Antibiotic
susceptibility of the strains was evaluated using the disk diffusion
method with 14 antibiotics and analyzed according the EUCAST
recommendations (Figure 1A). The strains were non-susceptible
(resistant or intermediate) to at least two different antibiotics
tested belonging to rifamycin, sulfonamide or nitrofuran classes.
All strains were found sensitive to the tested agents in β-lactam,
aminoglycosides and fosfomycin antimicrobial classes which are
commonly used to fight pseudomonal infections. In addition to
antibiotic sensitivity, the impact of a commercial bacteriophage
cocktail on the strains was evaluated. Interestingly, all the strains
were sensitive to the cocktail resulting in drastic decreases in
cell density (Supplementary Figure 1). These results confirm
that bacteriophage-based therapy may constitute an alternative
to antibiotherapies in case of resistant infections.
Isolation and Characterization of
Phage-Resistant Variants
Although bacteriophages were virulent to all four strains,
resistance phenomena were rapidly observed after exposure
of PA14, B10, C5, and C11 to three different concentrations
of phage cocktail for 16 h. For PA14, B10, and C11 one
mutant was isolated from each strain: PA14R1, B10R1, and
C11R1, respectively. Three different mutants, presenting different
phenotypes, were isolated from C5: C5R1, C5R2, and C5R3. The
newly isolated mutants were cultured in the presence of the
same amount of phage cocktail as that used for their isolation
to confirm their resistance (i.e., 100 µl for PA14 and PA14R1,
50 µl for B10 and B10R1 and 10 µl for C5, C5R1, C5R2,
C5R3, C11, and C11R1). Cell density was compared to the
initial strains in the presence of phages after a 16-h culture
by measuring the OD 600 nm (Figure 2). In the presence of
phages, growth was 4 to 7 times higher for all mutants than for
parental strains (Figure 2). The resistance of the isolated mutants
against the phage cocktail was thereby clearly highlighted
(Figure 2). Antibiotic sensitivity patterns of the phage-resistant
strains were further evaluated (Figure 1B). As for parental
isolates, phage resistant strains were non-susceptible (resistant or
intermediate) to at least two different antibiotics tested belonging
to rifamycin, sulfonamide or nitrofuran classes. Phage-resistant
strains were found to be sensitive to the tested agents in β-lactam,
aminoglycosides, cephalosporins, carbapenems and fosfomycin
antimicrobial classes. As noticed for B10, B10R1 showed
intermediate resistance to rifampicin while all other strains
were resistant to this antibiotic. Interestingly, the acquisition of
bacteriophage resistance was detrimental to antibiotic resistance
in the resistant clones isolated from C5. C5R1, C5R2, and
C5R3 lost their resistance against doxycycline and ciprofloxacin,
C5R1 being also sensitive to nitrofurantoin conversely to C5,
C5R2, or C5R3. Similarly, C11R1 exhibited a lower tolerance to
trimethoprim/sulfamethoxazole and doxycycline than C11.
Quenching Virulence Factors of
Antibiotic or Phage Resistant Clones
in vitro
The QQ effect of SsoPox-W263I on P. aeruginosa isolates PA14,
C5, C11, B10 and their bacteriophage resistant counterparts
was investigated by measuring the production of three typical
virulence factors in vitro: pyocyanin, protease, elastase as well as
biofilm production. Under the tested conditions, the addition of
SsoPox-W263I significantly reduced the three virulence factors
for all strains compared to controls (Figures 3A–C). All tested
strains produced detectable levels of pyocyanin and elastolytic
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FIGURE 1 | Interpretative zone diameters (mm) of 14 antibiotics used on clinical isolates of Pseudomonas aeruginosa (A) and their associated phage-resistant
mutants (B). Susceptibility is expressed as Resistant (red), Intermediate (orange), Sensitive (green).
FIGURE 2 | Growth of phage resistant (gray) and the associated parental strains (black) in presence of phage cocktail. For each strain, bars represent the mean
density (OD 600 nm) after 16 h of incubation in MOPS glutamate with phage cocktail. Error bars represent the standard deviations of three replicated experiments.
∗p-values < 0.05; ∗∗∗p-values < 0.001 according to Student’s t-test or ANOVA analysis.
activity. Pyocyanin levels were reduced by more than 75% in
all strains upon enzymatic treatment, while elastase levels were
reduced by at least 60% in nine out of ten strains with the
addition of SsoPox-W263I (C5 elastase level being reduced by
only 25%). Proteolytic activity was detectable for all tested
strains but one: the parental isolate C5 which did not produce
sufficient levels of proteases with or without SsoPox-W263I
treatment to be detected. Conversely, the three phage-resistant
derivatives obtained from C5 had each detectable protease
activity in the absence of enzyme and this activity was completely
extinguished by the addition of SsoPox-W263I (Figure 3A).
Biofilm production was significantly reduced by more than 70%
in six strains when treated with SsoPox-W263I (Figure 3D).
Interestingly, the production of these four factors differed
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FIGURE 3 | Effect of SsoPox-W263I on virulence factors of phage resistant mutants (gray) and the associated parental strains (black) in vitro. For each strain, bars
represent the mean of protease (A), elastase (B), pyocyanin (C) and biofilm (D) levels of three experiments for treated culture with 0.5 mg ml−1 SsoPox-W263I
(striped bar) or inactive mutant 5A8 as negative control (empty bar). ND: not detected. Error bars represent the standard deviations of three experiments.
∗p-values < 0.05; ∗∗p-values < 0.01; ∗∗∗p-values < 0.001 according to Student’s t-test.
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between the parental strains and their phage-resistant derivatives
(Figure 3). It appears that the selection for phage-resistant
clones did not result in the selection for mutants with only
increased or only decreased biofilm formation. Similarly phage-
resistant mutants did not all increase nor decrease virulence
factor secretion as compared to their parental strains. Thereby
no common trade-off due to the selection of phage resistant
bacteria can be drawn at the level of these four phenotypic traits.
Altogether, these results show the efficiency of SsoPox-W263I in
reducing the amount of three virulence factors characteristic of P.
aeruginosa and modulating the production of biofilm in vitro in
both antibiotic and phage-resistant isolates.
Evaluation of Quorum Quenching in
Amoeba, Virulence Model
To further confirm the potential of SsoPox-W263I to decrease
the virulence of bacterial isolates, the in vivo protecting effect
of the enzyme was assayed using the amoeba A. polyphaga. The
virulence of treated and control bacteria toward amoeba was
assayed by measuring the propagation of A. polyphaga on a plate
flooded by a pretreated bacterial lawn (Fenner et al., 2006).
Overall, SsoPox-W263I treatment decreased the virulence
toward A. polyphaga of 9 out of 10 strains. No effect of
QQ was observed for C11, for which virulence toward
A. polyphaga remained unchanged with or without SsoPox-
W263I treatment, but its phage resisting mutant C11R1
recovered a high sensitivity to the amoeba upon treatment
(Figure 4). C5, C5R1, and PA14R1 were initially not
virulent enough to prevent the propagation of amoeba in
the control condition; however, treatment by SsoPox-W263I
significantly enhanced its expansion (Figure 4). Consistently
with in vitro observations on virulence factor production,
the results obtained in vivo confirmed that parental and
resistant strains behave differently, especially for PA14 and C5
(Figure 4). SsoPox-W263I treatment showed a benefic effect
in all but one case and no negative effects were observed,
highlighting the efficiency of the QQ treatment in reducing
the virulence of antibiotic and phage resistant isolates in an
in vivo model.
Combined Effect of Enzymatic and
Antimicrobial Treatment
Considering that PA14 displayed antibiogram comparable to
most clinical isolates tested in this study, PA14 and its phage
resistant mutant PA14R1 were further used as representative
candidates to evaluate the combined effect of SsoPox-W263I
and antibiotic treatment using the amoeba infection model
(Figure 5), then the combined effect of SsoPox-W263I and phage
treatment was also assayed (Figure 6). As observed in our first
experiment, with an enzyme concentration of 500 µg ml−1, QQ
increases the sensitivity toward amoeba. Hence, to better assay
the combined effect of enzymatic and antimicrobial treatments,
lower doses of SsoPox-W263I were considered. Thus, following
a dose response experiment on PA14, 10 µg ml−1 of SsoPox-
W263I was used with antimicrobial as it had a lower impact on
the virulence (Supplementary Figure 2).
Synergistic effect was observed with a treatment of SsoPox-
W263I and 25 mg ml−1 ciprofloxacin on PA14, PA14R1
(Figure 5). At these concentrations, each treatment alone had
no effect on the virulence of PA14 against the amoeba and
the amoeba could not grow. However, with the combined
treatment (ciprofloxacin + SsoPox-W263I), the amoeba was
able to completely colonize the Petri dish in 6 and 7 days,
respectively, for PA14. PA14R1 virulence was slightly impacted
by the antibiotic treatment alone or the QQE treatment alone,
but the highest effect was observed with the combined treatment:
the Petri dish limit (8.5 cm) was reached 1 day earlier than with
the QQE treatment alone, and the growth of amoeba started
after 1 day with the combined treatment against 4 days with
ciprofloxacin alone.
As the composition of the commercial cocktail was toxic for
amoeba, PA14 lytic phages were purified from the cocktail and
concentrated to 108 PFU ml−1. To test the combined effect of
SsoPox-W263I and phages, 8Intesti-PA14 was used alone or in
combination with the enzyme against PA14 and PA14R1. The
isolated phages did not impact the growth of the amoeba. For
both PA14 and PA14R1, amoeba growth was faster with SsoPox-
W263I alone, yet the combined treatment led to a further increase
of amoeba growth (Figure 6).
DISCUSSION
In this study, four strains of P. aeruginosa were used,
including three clinical isolates from diabetic foot infections.
The antibiotic resistance profiles of the strains revealed that
all the clinical isolates presented a significant tolerance to
rifampicin, trimethoprim/sulfamethoxazole and nitrofurantoin,
confirming previous observations regarding the increasing rate
of multi-resistance in diabetic foot infections in the recent years
(Lipsky, 2016).
To address antibioresistance issues, bacteriophages and QQ
have emerged as promising therapeutic approaches. As with
antibiotics, the use of bacteriophages suffers from rapid resistance
phenomena such as the formation of a biofilm, the modification
of phage receptor expression that can reduce phage entry
(Chapman-McQuiston and Wu, 2008), or the cell adaptive
inducible CRISPR-Cas (clustered regularly interspaced short
palindromic repeat and CRISPR associated proteins) system that
recognizes and degrades phage DNA (Barrangou et al., 2007).
Interestingly, it has been extensively demonstrated that QQ
reduces biofilm formation in P. aeruginosa, thereby increasing
antimicrobial treatment efficacy, and a recent study has
underlined that QS disruption can also decrease phage resistance
by inhibiting QS stimulation of the CRISPR-Cas system
(Høyland-Kroghsbo et al., 2017). The efficacy of SsoPox-W263I
to modulate CRISPR-Cas system regulation of proteobacteria,
including P. aeruginosa, was recently demonstrated (Mion
et al., 2019). In addition, recent studies have shown that
even without involvement of CRISPR-Cas defense, the phage
infection outcome could be different in QS-deficient mutant of
P. aeruginosa than in wild type strains (Qin et al., 2017; Saucedo-
Mora et al., 2017). As antibiotic or phage resistance can induce
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FIGURE 4 | Effect of SsoPox-W263I on the virulence of clinical isolates (black) and phage resistant mutants (gray) against A. polyphaga Linc AP1. For each strain,
curves represent the mean diameter of amoeba at different days of three experiments after incubation in presence of bacteria treated by 0.5 mg ml−1 of mutant
SsoPox-W263I (dotted line) or inactive mutant 5A8 (full line) as negative control. Error bars represent the standard deviations of three experiments. ∗p-values < 0.05;
∗∗p-values < 0.01; ∗∗∗p-values < 0.001 according to ANOVA analysis.
Frontiers in Microbiology | www.frontiersin.org 8 September 2019 | Volume 10 | Article 2049
fmicb-10-02049 August 31, 2019 Time: 16:11 # 9
Mion et al. Lactonase to Fight Resistant Bacteria
FIGURE 5 | Combinatory effect of SsoPox-W263I and ciprofloxacin on the virulence of clinical isolates and phage resistant mutants against A. polyphaga Linc AP1.
For each strain, curves represent the mean diameter of amoeba at different days after incubation in presence of bacteria without treatment (red) or treated with
25 mg ml−1 ciprofloxacin (orange), 10 µg ml−1 SsoPox-W263I (blue), or 10 µg ml−1 SsoPox-W263I and 25 mg ml−1 ciprofloxacin (green). Error bars represent the
standard deviations of three experiments.
FIGURE 6 | Combinatory effect of SsoPox-W263I and isolated phage on the virulence of PA14 and its phage resistant mutant against A. polyphaga Linc AP1. For
each strain, curves represent the mean diameter of amoeba at different days after incubation in presence of bacteria without treatment (red) or treated with 107
PFU ml−1 8Intesti-PA14 (orange), 10 µg ml−1 SsoPox-W263I (blue), or 10 µg ml−1 SsoPox-W263I and 107 PFU ml−1 8Intesti-PA14 (green). Error bars represent
the standard deviations of three experiments.
life-threatening complications, we evaluated the potential of QQ
to act as an alternative therapeutic approach.
First, we selected six mutants derived from the four initial
strains as phage resistant toward a commercial phage cocktail.
The virulence profiles of each strain were then evaluated
and the efficacy of three therapeutic approaches (antibiotics
with ciprofloxacin, bacteriophages and QQ with SsoPox-
W263I) on the different strains was further assessed alone or
in combinations.
In several cases bacteriophage resistance did not affect
antibiotic resistance, although the selection pressure induced by
the phage cocktail resulted in a loss of resistance to ciprofloxacin
and doxycycline in the mutant strains isolated from C5. This
evolutionary trade-off is coherent with a previous study, where
the phage OMKO1 which targets OprM, the porin of a multi-drug
efflux system of P. aeruginosa as receptor-binding site, selected
resistant bacteria harboring a change in the efflux mechanism
with increased sensitivity to different antibiotic classes, such as
tetracycline and fluoroquinolone (Chan et al., 2016).
To determine the potential of QQ treatment on the different
strains, four QS-regulated traits, biofilm formation and the
production of three virulence factors (pyocyanin, protease
and elastase) were measured in vitro. As reported in other
studies, some phage resistant bacteria such as C5R1, C5R2,
and C5R3 exhibited higher level of virulence factor production
than the initial strain (Hosseinidoust et al., 2013). The ability
of SsoPox-W263I as QQ agent to decrease virulence in the
different strains was also assayed. The QQ treatment significantly
reduced the production of the virulence factors for the initial
strains as well as their phage resistant mutants, showing that
bacteria resistant to phage treatment conserved a functional
QS system which can be inhibited by enzyme-mediated QQ.
Strains harboring a higher virulence profile were also efficiently
quenched using SsoPox-W263I. In order to correlate in vitro
production of virulence factors, biofilm formation and in vivo
virulence, an amoeba-based assay was developed. Amoeba
are eukaryotic organisms able to feed on bacteria. Their
phagocytosis and digestion mechanisms are similar to those
of macrophage bacterial elimination (Greub and Raoult, 2004),
thus amoeba are frequently used to test in vivo virulence of
bacteria (Rémy et al., 2018). The model of A. polyphaga feeding
on P. aeruginosa, where the growth of the amoeba directly
indicates the pathogenicity level of the bacteria, was chosen
to assess the efficiency of QQ treatment with SsoPox-W263I.
The results showed that the inhibition of virulence by the QQ
treatment was efficient for 9 out of 10 strains, allowing the
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growth of the amoeba, independently from the resistance profiles
to antibiotics or bacteriophages. Interestingly, P. aeruginosa
was previously proved to use type III secretion system (T3SS)
to kill biofilm-associated amoebae potentially suggesting that
differences observed upon enzymatic treatment could be related
in the modification of T3SS regulation (Matz et al., 2008).
Although variable enzyme effects on virulence factor production
or biofilm formation were observed in vitro depending on the
strains, our results indicate that QQ is efficient in vivo on most of
the antibiotic or phage resistant clinical isolates. This highlights
the potential of enzymatic QQ treatment as an interesting
alternative in case of therapeutic dead ends.
Furthermore, we evaluated the potential of SsoPox-W263I
to act as a complement of antibiotics or bacteriophages to
counteract P. aeruginosa virulence toward A. polyphaga. Using
lower concentrations of SsoPox-W263I, the combination of
QQ and ciprofloxacin enhanced the growth of the amoeba for
ciprofloxacin-sensitive strains PA14 and PA14R1 as compared to
the antibiotic or the enzymatic treatment alone. Consistently with
previous reports using the lactonase from Bacillus sp. ZA12 with
ciprofloxacin in a murine burn infection model (Gupta et al.,
2015), our results show that enzymatic QQ works in synergy
with fluoroquinolones in sensitive strains decreasing efficiently
the amount of antibiotics required to fight bacterial infections.
In addition to antibiotics, the synergy of SsoPox-W263I
with bacteriophages was underlined. Synergistic effects were
observed when P. aeruginosa PA14 was treated by the combined
actions of isolated phage 8Intesti-PA14 and SsoPox-W263I.
Interestingly, the synergy was also observed on PA14R1 strain,
which was resistant to the phage cocktail. In concordance with
these observations, recent reports showed close relationships
between QS and phage tolerance mechanisms in P. aeruginosa
(Mion et al., 2018).
Altogether, the results obtained in vitro and in vivo show
that SsoPox-W263I is efficient to decrease bacterial virulence
in model and clinical isolates of P. aeruginosa and constitute a
proof of concept suggesting that enzymatic QQ can strengthen
the therapeutic arsenal available against P. aeruginosa infections
by enhancing the efficiency of available treatments including
bacteriophages or antibiotics. In addition, it has been shown
that this enzyme, issued from an extremophilic organism, resists
harsh industrial conditions (Rémy et al., 2016) confirming its
tremendous potential for biopharmaceutical applications and
should now be evaluated on mammalian models in order to reach
clinical trials.
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